-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Jan Hedner and Ludger Grote, Sahlgrenska Institute, University of Gothenburg
A new study from the University of Gothenburg paves the way for the first use of drugs to treat sleep apnea
The tested treatment is carbonic anhydrase (CA) inhibition, an enzyme that maintains the balance between carbonic acid and carbon dioxide in the body
Previous studies have not systematically tested whether CA inhibitors can also be used to treat obstructive sleep apnea
reduce apnea
The results showed that, overall, the treatment reduced the number of apneas and promoted nocturnal oxygenation
The findings, along with the established safety data for sulfa drug, support continued research into CA inhibition as a new potential treatment for obstructive sleep apnea
"In the patients who received the high dose of the drug, the number of apnea decreased by about 20 per hour
In fact, in the class of CA inhibitors, there are several approved drugs available on the market, making it possible to rapidly develop an approved drug for the treatment of sleep apnea
treatment plan needs
Today, the treatment for sleep apnea is either oral device therapy or a CPAP (continuous positive airway pressure) mask
These treatment options take time to get used to because they are often considered invasive or cumbersome
German pharmaceutical company desittin Arzneimittel GmbH funded the trial, and the findings are published in the American Journal of Respiratory and Critical Care Medicine
